Navigation Links
VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
Date:10/7/2010

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom Scores (TNSS) compared to placebo (p=0.012). TNSS is the standard endpoint used in allergy trials that takes into account nasal congestion, itching, sneezing and rhinorrhea. VTX-1463 is a selective TLR8 agonist that is delivered intranasally on a weekly basis.

"It's encouraging to see such robust results from this new selective TLR8 agonist," said Friedrich Horak, M.D., Professor of the Medical University Vienna and Vienna Challenge Chamber (VCC) in Vienna, Austria, and principal investigator of this study. "Given that allergic rhinitis impacts a substantial portion of the overall population, a potential drug like VTX-1463 that is administered intranasally once a week could provide an important advantage for patients."

The clinical trial assessed safety and efficacy of VTX-1463 in a randomized, placebo controlled study in 80 patients with confirmed allergy to grass pollen in the Vienna Challenge Chamber. VTX-1463 was evaluated as a stand-alone agent administered once-weekly in four doses intranasally. Further details of the trial and results will be presented at an upcoming scientific meeting.

"These data provide clinical proof-of-concept for further development of VTX-1463 in allergic rhinitis as well as the rationale to potentially explore other allergic indications," said Robert Hershberg, M.D., Ph.D., Co-founder and Chief Medical Officer at VentiRx. "The VTX-1463 data combined with recent data generated with VTX-2337 in oncology validates TLR8 as an important and relevant target in human diseases."

"VTX-1463 is the first TLR8 agonist for the treatment of allergies," said Michael Kamdar, Co-Founder and Chief Business Officer at VentiRx. "Given the potential for weekly dosing that is allergen independent, VTX-1463's emerging product profile is markedly different from existing treatments and may be very beneficial for allergic patients."

About VCC

The Vienna Challenge Chamber is an Allergen Exposure Chamber covered by Canadian Patent No. 2,416,328, EU Patent No. 1,335,750 and US patent pending.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory and inflammatory diseases. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization with operations in San Diego and Seattle. For additional information, please visit www.ventirx.com.


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
7. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
9. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
10. Transcept Pharmaceuticals to Present at BIO Investor Forum
11. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/30/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will present ... Conference on Tuesday, June 13, 2017, in Rancho ... president and chief executive officer, is scheduled to present at ... can be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay ... event through September 13, 2017. ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
Breaking Medicine Technology:
(Date:6/23/2017)... , ... June 23, 2017 , ... ... surgeon practicing in Newburgh, New York, has recently begun offering three new minimally ... offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today ... is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). ... Restaurant Group who owns three other locations in the Topeka and Bonner Springs, Kan. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
(Date:6/23/2017)... San Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... Conference on 26th June, 2017 from 9 am to 3 pm to present to ... curriculum. The program is an original curriculum project led by The Health Improvement ...
Breaking Medicine News(10 mins):